Pharmacy - Dysmenorrhea

PATIENT DETAILS:
Name: Mr. Carter
Phone number: 
Personal Health Number (PHN): 

GENERAL:
PharmaNet has been checked. Eligibility is confirmed.

Objective:
REASON FOR VISIT:
Follow-up for chronic lower back pain and depression.

PATIENT ASSESSMENT:
Mr. Carter reports persistent lower back pain that is present throughout the day, with increased severity in the mornings and after prolonged sitting. The pain interferes with sleep. He describes a low mood, anhedonia, social withdrawal, and significant fatigue. He denies active suicidal ideation but expresses passive thoughts of not wanting to wake up. Lumbar spine magnetic resonance imaging demonstrates mild degenerative disc disease without surgical indication. Physical assessment findings are not documented.

RED FLAGS/REFERRAL INDICATIONS:
No active suicidal ideation is present.

Subjective:
PAST MEDICAL HISTORY:
Mr. Carter has a history of chronic lower back pain and depression. No history of renal or liver impairment is reported. No information regarding potential pregnancy is applicable.

CURRENT MEDICATIONS:
No prior use of serotonin-norepinephrine reuptake inhibitor or similar medications. No other current medications are reported. PharmaNet has been checked.

ALLERGIES:
No allergies to drugs, foods, or environmental agents are reported.

Assessment:
DIAGNOSIS:
Chronic lower back pain and major depressive disorder.

Plan:
RECOMMENDATIONS:
- Mr. Carter is educated about the relationship between chronic pain and depression. Non-pharmacological management including continuation of physical therapy and referral for cognitive behavioral therapy is discussed. 
- Treatment: Initiation of duloxetine at a low dose is recommended for management of both mood and neuropathic pain. A short-term muscle relaxant is considered for adjunctive pain control. Instructions regarding medication titration and monitoring for side effects are provided. 
- Mr. Carter is advised of the importance of not exceeding the recommended dosage of prescribed medications due to risks of toxicity, including potential renal or liver damage.

MONITORING/FOLLOW UP:
- Follow up is recommended within 2 to 3 weeks to assess efficacy of treatment and monitor for adverse drug reactions.
- Mr. Carter is advised to contact his primary care provider if there is no response to treatment or if symptoms worsen.

Date:
2026-02-09

PHARMACY INFORMATION:
Pharmacy name: 
Pharmacy phone number: 
Pharmacy address: 
Pharmacist name: 
Pharmacist license number: